Abstract
SummaryAt the ASCO 2020 virtual meeting, multiple clinically relevant studies were presented addressing open questions in the head and neck cancer field: Are de-escalation strategies feasible in low risk patients? What is the appropriate platinum dose in combination with radiotherapy in high-risk patients suffering from locally advanced disease? Is immunotherapy the first line standard of care for all patient in the recurrent/metastatic setting? This article summarizes the most significant head and neck cancer studies presented at the ASCO 2020 virtual meeting and discusses the data in the context of the current literature.
Highlights
Head and neck cancer (HNSCC) data presented at this year’s virtual American Society of Clinical Oncology (ASCO) scientific meeting were not entirely practice changing, a couple of open questions were clarified and/or the current evidence confirmed
The European Society of Medical Oncology (ESMO) MCBS as rated by the author is B, i.e., relevant clinical benefit in the curative setting
The randomized Japanese JCOG1008 phase II/III study aimed at demonstrating the noninferiority of weekly 40 mg/m2 cisplatin to conventional standard of care (SOC) highdose 100 mg/m2 cisplatin administered every 3 weeks in stage III/IV HNSCC patients, who were treated with postoperative radiotherapy due to positive margins or extracapsular extension
Summary
Received: 25 October 2020 / Accepted: 10 January 2021 / Published online: 27 January 2021. Summary At the ASCO 2020 virtual meeting, multiple clinically relevant studies were presented addressing open questions in the head and neck cancer field: Are de-escalation strategies feasible in low risk patients? What is the appropriate platinum dose in combination with radiotherapy in high-risk patients suffering from locally advanced disease? Is immunotherapy the first line standard of care for all patient in the recurrent/metastatic setting? This article summarizes the most significant head and neck cancer studies presented at the ASCO 2020 virtual meeting and discusses the data in the context of the current literature. Keywords Recurrent/metastatic HNSCC · Locally advanced HNSCC · Immunotherapy · Radiotherapy · Surgery
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
